Despite No Ties, Vivos Feels Heat from Widely Publicized Oral Appliance Lawsuit 

Vivos Therapeutics Inc, a maker of oral appliances for breathing-related sleep disorders, reported a decline in product revenue and Vivos Integrated Provider (VIP) enrollments in the second quarter. The company attributed this dip to governmental investigations into third parties offering non-US Food and Drug Administration (FDA)-approved sleep apnea treatments, despite having no involvement. The declines…

Read More

How Sleep Illuminates Neurodegenerative Disease Pathways, and Vice Versa

By Risa Kerslake, BSN-RN  Many people with neurodegenerative diseases have altered sleep due to neurodegenerative changesbrought on by damage or loss of neurons in the sleep-controlling centers of the brain or as a result of disease symptoms.1 For example, Parkinson’s disease-related movement difficulties make it challenging to get comfortable in bed, while Alzheimer’s disease-linked long…

Read More

Centessa to Present Preclinical Data for Investigational Orexin Agonist for Narcolepsy

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company focused on discovering and developing medicines for a range of indications, reported second-quarter business highlights, spotlighting progress for ORX750, an oral selective orexin-2 receptor (OX2R) agonist in development for narcolepsy and other sleep disorders. “This is an exciting time for Centessa as we continue to execute across our…

Read More